Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&U/Searle Mingling Sales Forces To Promote Detrol In Advance Of Merger

Executive Summary

Searle and Pharmacia & Upjohn are getting a head start on their proposed merger through a co-promotion deal for P&U's overactive bladder therapy Detrol.

You may also be interested in...



Detrol Sales Potential Could Be $1 Bil. With Once-Daily Indication, P&U Says

The sales potential of Pharmacia & Upjohn's overactive bladder treatment Detrol (tolterodine) could be up to half a billion dollars greater than previous projections, pending approval of a once-daily formulation.

Detrol Sales Potential Could Be $1 Bil. With Once-Daily Indication, P&U Says

The sales potential of Pharmacia & Upjohn's overactive bladder treatment Detrol (tolterodine) could be up to half a billion dollars greater than previous projections, pending approval of a once-daily formulation.

Searle Oncology Given Boost By Pending P&U Merger, Antibody Deal

Searle will create a platform for new oncologics development through a research collaboration with Cambridge Antibody Technology.

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel